1. Elleuche S, Pöggeler S. Inteins, valuable genetic elements in molecular biology and biotechnology. App microbio biotechno 2010; 87(2): 479-89.
2. Chong S, Shao Y, Paulus H, Benner J, Perler FB, Xu M-Q. Protein Splicing Involving the Saccharomyces cerevisiae VMA Intein The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biological Chemistry 1996; 271(36): 22159-68.
3. Klabunde T, Sharma S, Telenti A, Jacobs WR, Sacchettini JC. Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. Nature Structural & Molecular Biology 1998; 5(1): 31-6.
4. Wood DW, Camarero JA. Intein applications: from protein purification and labeling to metabolic control methods. J Biologic Chemistry 2014; 289(21): 14512-519.
5. Chong S, Mersha FB, Comb DG, Scott ME, Landry D, Vence LM, et al. Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element. Gene 1997; 192(2): 271-81.
6. Chong S, Montello G, Zhang A, Cantor EJ, Liao W, Xu M-Q, et al. Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic acids Res 1998; 26(22): 5109-15.
7. Southworth MW, Amaya K, Evans TC, Xu M-Q, Perler FB. Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein. Biotechniques 1999; 27(1): 110-04.
8. Li Y. Self-cleaving fusion tags for recombinant protein production. Biotechno letters 2011; 33(5): 869-81.
9. 9- Kreitman RJ. Immunotoxins for targeted cancer therapy. The AAPS J 2006; 8(3): E532-E51.
10. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clinic cancer Res 2000; 6(2): 326-34.
11. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer*. Annu Rev Med 2007; 58: 221-37.
12. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nature Reviews Cancer. 2006; 6(7): 559-65.
13. Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics: Targets & Therapy 2008; 2(4): 717-24.
14. Knobler E. Current management strategies for cutaneous T-Cell Lymphoma. Clinics in dermatology 2004; 22(3): 197-208.
15. Amraee M, Zeinodini M, Soleimani M, Saeedinia AR. Cloning, expression, purification and toxicity assessment of diphtheria toxin - interleukin 2 fusion protein. J Polic Med 2015; (2): 125-32. [Persian]
16. Armstrong AW, Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Principles of pharmacology: the pathophysiologic basis of drug therapy. 3rd edition, Wolters Kluwer Health/Lippincott Williams Wilkins, Philadelphia, 2008.
17. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clinic pharmacokinetics 2005; 44(4): 331-47.
18. Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert review anticancer therapy 2007; 7(1): 11-7.
19. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nature biotechno 1998; 16(2): 153-57.
20. Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs 2013; 73(7): 755-65.
21. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England J Med 2004; 351(4): 337-45.
22. Gogarten JP, Senejani AG, Zhaxybayeva O, Olendzenski L, Hilario E. Inteins: structure, function, and evolution. Annual Rev Microbio 2002; 56(1): 263-87.
23. Elleuche S, Döring K, Pöggeler S. Minimization of a eukaryotic mini-intein. Biochemical and biophysical Res commu 2008; 366(1): 239-43.
24. Naumann TA, Savinov SN, Benkovic SJ. Engineering an affinity tag for genetically encoded cyclic peptides. Biotechnology and bioengineering 2005; 92(7): 820-30.
25. Tavassoli A, Benkovic SJ. Split-intein mediated circular ligation used in the synthesis of cyclic peptide libraries in E. coli. Nature protocols 2007; 2(5): 1126-33.
26. Banki MR, Gerngross TU, Wood DW. Novel and economical purification of recombinant proteins: Intein‐mediated protein purification using in vivo polyhydroxybutyrate (PHB) matrix association. Protein Sci 2005; 14(6): 1387-95.
27. Shi C, Meng Q, Wood D. A dual ELP-tagged split intein system for non-chromatographic recombinant protein purification. App Microbio Biotechno 2013; 97(2): 829-35